ALDEYRA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $5.98 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.38, a 46.15% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $9.99, a 30.08% increase year-over-year.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $7.68.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.00.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $8.99, a 13.80% increase from fiscal 2024.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $7.90, a 80.78% increase from fiscal 2023.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $4.37.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.98 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $5.38 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $8.99 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $8.99 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $8.99 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $9.99 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $7.90 10-K · filed 2025-02-28 | |||
| 2024-09-30 | $7.90 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $7.90 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $7.68 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $4.37 10-K · filed 2024-03-07 | |||
| 2023-09-30 | $0.55 10-Q · filed 2023-11-03 | |||
| 2020-09-30 | $6.72 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $6.72 10-Q · filed 2020-08-06 | |||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-10 | |||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |